GlassScriptPhysician profile
Lynda A Kolb
NPI 1427748284
$3,404.27
in general payments reported to CMS, 2019-2025
31 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,977 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.78 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $604.22 | 2024-2025 | Ingrezza |
| Ucb, INC. | $307.26 | 2024-2025 | Briviact, Rystiggo |
| Abbvie INC. | $304.62 | 2024-2025 | |
| Lundbeck LLC | $242.42 | 2024-2025 | Rexulti, Vyepti, Abilify Asimtufii |
| Eisai INC. | $237.88 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $203.94 | 2025 | Austedo Xr |
| Lilly USA, LLC | $171.39 | 2024-2025 | Amyvid, Kisunla |
| Axsome Therapeutics, INC. | $127.84 | 2025 | Auvelity |
| Acadia Pharmaceuticals INC | $109.29 | 2024-2025 | Nuplazid |
| Corium, LLC | $106.23 | 2024-2025 | Azstarys |
| Genentech USA, INC. | $104.88 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Sumitomo Pharma America, INC. | $97.44 | 2024 | Aptiom |
| Mdd US Operations, LLC | $96.46 | 2024-2025 | Gocovri, Apokyn |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.66 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $75.36 | 2024 | Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $74.30 | 2024 | Ampyra, Inbrija |
| Otsuka America Pharmaceutical, INC. | $53.97 | 2024-2025 | Rexulti |
| Kyowa Kirin, INC. | $52.07 | 2024 | Nourianz |
| Tanabe Pharma America, INC. | $49.40 | 2024 | |
| Janssen Pharmaceuticals, INC | $47.72 | 2025 | Spravato |
| Tms Neurohealth Centers INC. | $37.62 | 2025 | Tms Neurohealth Centers INC. |
| C2n Diagnostics, LLC | $31.43 | 2025 | Precivityad2 |
| Supernus Pharmaceuticals, INC. | $25.96 | 2025 | Qelbree |
| Bausch Health US, LLC | $22.80 | 2025 | Aplenzin, Wellbutrin |
| Argenx US, INC. | $22.09 | 2024 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $20.71 | 2024 | Xeomin, Inbrija |
| Tris Pharma INC | $19.87 | 2025 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $18.64 | 2024 | Keveyis |
| Impel Pharmaceuticals LLC | $18.27 | 2024 | Trudhesa |
| Biomarin Pharmaceutical INC. | $18.24 | 2024 | Vimizim |
| Idorsia Pharmaceuticals US INC | $16.29 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynda Kolb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.